Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients-Reference-Cited by-同舟云学术

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Lum Lawrence G.¹,Thakur Archana¹,Choi Minsig²,Deol Abhinav³,Kondadasula Vidya³,Schalk Dana¹,Fields Kristie³,Dufrense Melissa³,Philip Philip³,Dyson Gregory³,Aon Hussein D.⁴,Shields Anthony F.³

Affiliation:

1. Stem Cell Transplantation Program, Division of Oncology/Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA

2. Department of Oncology, Stony Brook University, Stony Brook, NY, USA

3. Department of Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University, Detroit, MI, USA

4. Department of Radiology, Barbara Ann Karmanos Cancer Institute and Wayne State University, Detroit, MI, USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1773201

Reference32 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

2. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine